Related Experiment Video
Updated: Jun 17, 2026
The Insect Galleria mellonella as a Powerful Infection Model to Investigate Bacterial Pathogenesis
Published on: December 11, 2012
A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis
Aurora Montali1, Francesca Berini1, Alessio Saviane2
1Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Abstract:
The increasing number of microorganisms that are resistant to antibiotics is prompting the development of new antimicrobial compounds and strategies to fight bacterial infections. The use of insects to screen and test new drugs is increasingly considered a promising tool to accelerate the discovery phase and limit the use of mammalians. In this study, we used for the first time the silkworm, Bombyx mori, as an in vivo infection model to test the efficacy of three glycopeptide antibiotics (GPAs), against the nosocomial pathogen Staphylococcus epidermidis. To reproduce the human physiological temperature, the bacterial infection was performed at 37 °C and it was monitored over time by evaluating the survival rate of the larvae, as well the response of immunological markers (i.e., activity of hemocytes, activation of the prophenoloxidase system, and lysozyme activity). All the three GPAs tested (vancomycin, teicoplanin, and dalbavancin) were effective in curing infected larvae, significantly reducing their mortality and blocking the activation of the immune system. These results corroborate the use of this silkworm infection model for the in vivo studies of antimicrobial molecules active against staphylococci.
Insights
Silkworms offer a novel in vivo model for testing new antibiotic drugs. This study shows glycopeptide antibiotics effectively treat Staphylococcus epidermidis infections in silkworms, reducing mortality and immune response.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Antibiotic resistance necessitates novel antimicrobial development.
- Insect models offer a promising alternative to mammalian testing for drug screening.
- Staphylococcus epidermidis is a significant nosocomial pathogen.
Purpose of the Study:
- To evaluate the efficacy of glycopeptide antibiotics (GPAs) against Staphylococcus epidermidis using the silkworm (Bombyx mori) as an in vivo model.
- To assess the impact of GPAs on larval survival and key immunological markers.
Main Methods:
- Silkworms were infected with Staphylococcus epidermidis at 37°C.
- Larval survival rates were monitored over time.
- Immunological markers including hemocyte activity, prophenoloxidase system activation, and lysozyme activity were measured.
Main Results:
- All three tested GPAs (vancomycin, teicoplanin, dalbavancin) demonstrated efficacy in treating silkworm infections.
- GPAs significantly reduced larval mortality.
- Treatment with GPAs effectively inhibited the activation of the silkworm immune system.
Conclusions:
- The silkworm (Bombyx mori) serves as a viable in vivo model for evaluating antimicrobial compounds against staphylococci.
- This model accelerates antimicrobial drug discovery and reduces reliance on mammalian testing.
- GPAs show significant potential for treating Staphylococcus epidermidis infections.
More Related Videos
10:19Establishment and Optimization of a High Throughput Setup to Study Staphylococcus epidermidis and Mycobacterium marinum Infection as a Model for Drug Discovery
Published on: June 26, 2014
06:19Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
Published on: October 11, 2024
